Condition
NK/T-cell Lymphoma clinical trials and research
As of November 12, 2026, Find a Trial lists 4 NK/T-cell Lymphoma clinical trials that are recruiting, in China. By phase: Phase 2 (2), Phase 1/2 (1), Early Phase 1 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 4Clinical trials
- 1Country
Newest NK/T-cell Lymphoma clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma | Phase 1/2 | Shanghai, Shanghai Municipality | Recruiting | Mar 31, 2026 |
| Anti-EBV autologous TCR-T cell injection for relapsed or refractory EBV-positive lymphoma | Early Phase 1 | Shanghai | Recruiting | Sep 9, 2025 |
| Dexamethasone, azacitidine, pegaspargase and tislelizumab with radiotherapy for stage I–II extranodal NK/T‑cell lymphoma | Phase 2 | Beijing and 2 other locations | Recruiting | Jun 3, 2025 |
| Treatment of advanced NK/T-cell lymphoma with selinexor and chemotherapy | Phase 2 | Beijing, Haidian | Recruiting | Apr 27, 2023 |
All recruiting trials (4)
-
Tislelizumab plus Zeprumetostat in relapsed or refractory NK/T-cell lymphoma
This study tests whether combining tislelizumab with zeprumetostat can help patients with relapsed or refractory NK/T-cell lymphoma after prior chemotherapy.
-
Anti-EBV autologous TCR-T cell injection for relapsed or refractory EBV-positive lymphoma
This trial will test whether injections of a patient's own anti-EBV TCR-T cells are safe and help adults (18–70) with relapsed or refractory EBV-positive lymphoma who have HLA-A11:01.
-
Dexamethasone, azacitidine, pegaspargase and tislelizumab with radiotherapy for stage I–II extranodal NK/T‑cell lymphoma
This treatment plan will test whether combining four drugs (dexamethasone, azacitidine, pegaspargase, and tislelizumab) with radiotherapy helps adults with stage I–II extranodal NK/T‑cell lymphoma.
-
Treatment of advanced NK/T-cell lymphoma with selinexor and chemotherapy
This study tests if adding a new drug called selinexor to standard chemotherapy can help people with advanced NK/T-cell lymphoma feel better and improve their treatment results.
Related topics
Quick answers
How many NK/T-cell Lymphoma clinical trials are recruiting right now?
4, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
All of them have sites in China. Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 1/2: 1, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.